We herein report that a single dose of the anti-IL-2Rα MAb daclizumab, given concomitant with epidermal growth factor receptor variant III (EGFRvIII) targeted vaccination in a randomized saline-controlled pilot study, has the capacity to safely and effectively deplete CD4+Foxp3+ TRegs in TMZ-treated patients with GBM without impairing vaccine-induced immune responses (Figure 1). Here, IL2RA is linked to glioblastoma.